Biologically Active Small Molecules

A metabolite of cefpodoxime proxetil, the oral third generation cephalosporin antibiotic that demonstrates potent activity against most Gram-positive and Gram-negative bacteria (MIC90 ranges from 0.015-8 &microg/ml).

A metabolite of cefpodoxime proxetil, the oral third generation cephalosporin antibiotic that demonstrates potent activity against most Gram-positive and Gram-negative bacteria (MIC90 ranges from 0.015-8 &microg/ml).

A metabolite of cefpodoxime proxetil, the oral third generation cephalosporin antibiotic that demonstrates potent activity against most Gram-positive and Gram-negative bacteria (MIC90 ranges from 0.015-8 &microg/ml).

A &beta-lactam antibiotic that lyses actively-growing E. coli by binding specifically to penicillin-binding proteins 1a and b whose transglycosylase and transpeptidase activities are involved in cell elongation and septation.

A &beta-lactam antibiotic that lyses actively-growing E. coli by binding specifically to penicillin-binding proteins 1a and b whose transglycosylase and transpeptidase activities are involved in cell elongation and septation.

A &beta-lactam antibiotic that lyses actively-growing E. coli by binding specifically to penicillin-binding proteins 1a and b whose transglycosylase and transpeptidase activities are involved in cell elongation and septation.

A &beta-lactam antibiotic that lyses actively-growing E. coli by binding specifically to penicillin-binding proteins 1a and b whose transglycosylase and transpeptidase activities are involved in cell elongation and septation.

A broad-spectrum &beta-lactam antibiotic used for parenteral administration.

A broad-spectrum &beta-lactam antibiotic used for parenteral administration.

A broad-spectrum &beta-lactam antibiotic used for parenteral administration.

A broad-spectrum &beta-lactam antibiotic used for parenteral administration.

A third-generation, broad-spectrum cephalosporin antibiotic that disrupts the synthesis of the peptidoglycan layer of bacterial cell walls increases EAAT-2 pump expression in the CNS and reduces glutamatergic toxicity in both in vitro and in vivo